E. S. Pronker, T. C. Weenen, H. R. Commandeur, A. D. M. E. Osterhaus and H. J. H. M. Claassen, “The Gold Industry Standard for Risk and Cost of Drug and Vaccine Development Revisited,” Vaccine, Vol. 29, No. 35, 2011, pp. 5846-5849. doi:10.1016/j.vaccine.2011.06.051

has been cited by the following article:

• TITLE: Limits of Biotechnological Innovation

  AUTHORS: Kenneth Dimitri Satyagraha Fernald, Tamar Cheka Weenen, Kelsey Jean Sibley, Eric Claassen

  KEYWORDS: Biotechnology; Lifecycle; Saturation; Innovation; Biopharmaceuticals

  JOURNAL NAME: Technology and Investment, Vol.4 No.3, August 6, 2013

  ABSTRACT: During the past two decades the biopharmaceutical industry has been facing an innovation deficit, characterized by increasing research & development costs and stagnant productivity. From its inception, biotechnology has been expected to counter this deficit by its revolutionary science-based approach to drug discovery. For this study we gathered patent and product data related to the technological development of the first two biotechnologies: recombinant DNA technology and monoclonal antibody technology. We studied the technological lifecycles of these technologies in terms of scientific discoveries and inventions as well as product innovations. Results indicate that over the years inventions related to these technologies have simultaneously become less radical and less valuable. Furthermore, our analysis shows that these biotechnologies have reached a stage of technological limit or saturation, which may be followed by an innovation cliff. Now, more than ever, it is crucial to examine new strategies and opportunities for value creation, capturing, and delivery, within the biopharmaceutical industry.